First human GLP-1 gene therapy trial gets green light

(NewsNation) — Health authorities in Europe have given the green light for the first GLP-1 gene therapy trial to take place.

Fractyl Health received clinical trial authorization in the Netherlands this week to begin a first-in-human study of RJVA-001in patients with obesity and Type 2 diabetes.

“GLP-1 medicines have changed what is possible in obesity and type 2 diabetes, but they require chronic, high-dose systemic exposure that many patients cannot or do not sustain,” Dr. Harith Rajagopalan, CEO of Fractyl Health, said.

“RJVA-001 takes a different path: a potential one-time, pancreas-targeted gene therapy designed to enable the body to produce GLP-1 in........

© The Hill